Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199804663> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3199804663 abstract "Background: The bile acid (BA) pathway plays a role in regulation of food intake and glucose metabolism, based mainly on findings in animal models. Our aim was to determine whether the BA pathway is altered and correctable in human obesity and diabetes. Methods: We conducted 3 investigations: 1) BA receptor pathways were studied in NCI-H716 enteroendocrine cell (EEC) line, whole human colonic mucosal tissue and in human colonic EEC isolated by Fluorescence-activated Cell Sorting (ex vivo) from endoscopically-obtained biopsies colon mucosa; 2) We characterized the BA pathway in 307 participants by measuring during fasting and postprandial levels of FGF19, 7αC4 and serum BA; 3) In a placebo-controlled, double-blind, randomized, 28-day trial, we studied the effect of ileo-colonic delivery of conjugated BAs (IC-CBAS) on glucose metabolism, incretins, and lipids, in participants with obesity and diabetes.Results: Human colonic GLP-1-producing EECs express TGR5, and upon treatment with bile acids in vitro, human EEC differentially expressed GLP-1 at the protein and mRNA level. In Ussing Chamber, GLP-1 release was stimulated by Taurocholic acid in either the apical or basolateral compartment. FGF19 was decreased in obesity and diabetes compared to controls. When compared to placebo, IC-CBAS significantly decreased postprandial glucose, fructosamine, fasting insulin, fasting LDL, and postprandial FGF19 and increased postprandial GLP-1 and C-peptide. Increase in fecal BA was associated with weight loss and with decreased fructosamine.Conclusions: In humans, BA signaling machinery is expressed in colonic EECs, deficient in obesity and diabetes, and when stimulated with IC-CBAS, improved glucose homeostasis.Trial Registration: ClinicalTrials.gov number, NCT02871882, NCT02033875.Funding Statement: Research support and drug was provided by Satiogen Pharmaceuticals (San Diego, CA). The study was conducted in the clinical research unit (supported by Mayo Clinic Center for Clinical and Translational Science [CCaTS] grant UL1- TR000135). AA, MC, and NFL report grants (AA- C-Sig P30DK84567, K23 DK114460; MC- NIH R01 DK67071; NFL- R01 DK057993) from the NIH. JR was supported by an Early Career Grant from Society for Endocrinology.Declaration of Interests: AA is a stockholder in Gila Therapeutics, Phenomix Sciences and Lipiquester; he serves as a consultant for Rhythm Pharmaceuticals, General Mills, Gila Therapeutics. MC is a stockholder in Phenomix Sciences and serves as a consultant to Takeda, Allergan, Rhythm, Salix, Arena, Enterin. BG is a stockholder in Satiogen Pharmaceuticals. All other authors report no relevant financial or personal conflicts of interest.Ethics Approval Statement: Surgical specimens of fresh human colon were obtained from Tissue Bank at Addenbrooke's Hospital (Cambridge, UK) and used for experiments approved by the Research Ethics Committee. The study was approved by the Mayo Clinic Institutional Review Board, and all participants gave written informed consent." @default.
- W3199804663 created "2021-09-27" @default.
- W3199804663 creator A5002287956 @default.
- W3199804663 creator A5005124004 @default.
- W3199804663 creator A5005352016 @default.
- W3199804663 creator A5009875171 @default.
- W3199804663 creator A5010082559 @default.
- W3199804663 creator A5017598516 @default.
- W3199804663 creator A5021732112 @default.
- W3199804663 creator A5026060771 @default.
- W3199804663 creator A5034132009 @default.
- W3199804663 creator A5034412938 @default.
- W3199804663 creator A5041151250 @default.
- W3199804663 creator A5060455870 @default.
- W3199804663 creator A5073419503 @default.
- W3199804663 creator A5080725701 @default.
- W3199804663 creator A5082847181 @default.
- W3199804663 date "2020-01-01" @default.
- W3199804663 modified "2023-10-16" @default.
- W3199804663 title "Ileo-Colonic Delivery of Conjugated Bile Acids Improves Glucose Homeostasis <i>via</i> Colonic GLP-1-Producing Enteroendocrine Cells in Human Obesity and Diabetes" @default.
- W3199804663 doi "https://doi.org/10.2139/ssrn.3517409" @default.
- W3199804663 hasPublicationYear "2020" @default.
- W3199804663 type Work @default.
- W3199804663 sameAs 3199804663 @default.
- W3199804663 citedByCount "0" @default.
- W3199804663 crossrefType "journal-article" @default.
- W3199804663 hasAuthorship W3199804663A5002287956 @default.
- W3199804663 hasAuthorship W3199804663A5005124004 @default.
- W3199804663 hasAuthorship W3199804663A5005352016 @default.
- W3199804663 hasAuthorship W3199804663A5009875171 @default.
- W3199804663 hasAuthorship W3199804663A5010082559 @default.
- W3199804663 hasAuthorship W3199804663A5017598516 @default.
- W3199804663 hasAuthorship W3199804663A5021732112 @default.
- W3199804663 hasAuthorship W3199804663A5026060771 @default.
- W3199804663 hasAuthorship W3199804663A5034132009 @default.
- W3199804663 hasAuthorship W3199804663A5034412938 @default.
- W3199804663 hasAuthorship W3199804663A5041151250 @default.
- W3199804663 hasAuthorship W3199804663A5060455870 @default.
- W3199804663 hasAuthorship W3199804663A5073419503 @default.
- W3199804663 hasAuthorship W3199804663A5080725701 @default.
- W3199804663 hasAuthorship W3199804663A5082847181 @default.
- W3199804663 hasBestOaLocation W31998046632 @default.
- W3199804663 hasConcept C103395026 @default.
- W3199804663 hasConcept C126322002 @default.
- W3199804663 hasConcept C134018914 @default.
- W3199804663 hasConcept C185592680 @default.
- W3199804663 hasConcept C203014093 @default.
- W3199804663 hasConcept C2776398474 @default.
- W3199804663 hasConcept C2777180221 @default.
- W3199804663 hasConcept C2777391703 @default.
- W3199804663 hasConcept C3018667095 @default.
- W3199804663 hasConcept C46699223 @default.
- W3199804663 hasConcept C539455810 @default.
- W3199804663 hasConcept C555293320 @default.
- W3199804663 hasConcept C63645605 @default.
- W3199804663 hasConcept C71315377 @default.
- W3199804663 hasConcept C71924100 @default.
- W3199804663 hasConcept C90924648 @default.
- W3199804663 hasConceptScore W3199804663C103395026 @default.
- W3199804663 hasConceptScore W3199804663C126322002 @default.
- W3199804663 hasConceptScore W3199804663C134018914 @default.
- W3199804663 hasConceptScore W3199804663C185592680 @default.
- W3199804663 hasConceptScore W3199804663C203014093 @default.
- W3199804663 hasConceptScore W3199804663C2776398474 @default.
- W3199804663 hasConceptScore W3199804663C2777180221 @default.
- W3199804663 hasConceptScore W3199804663C2777391703 @default.
- W3199804663 hasConceptScore W3199804663C3018667095 @default.
- W3199804663 hasConceptScore W3199804663C46699223 @default.
- W3199804663 hasConceptScore W3199804663C539455810 @default.
- W3199804663 hasConceptScore W3199804663C555293320 @default.
- W3199804663 hasConceptScore W3199804663C63645605 @default.
- W3199804663 hasConceptScore W3199804663C71315377 @default.
- W3199804663 hasConceptScore W3199804663C71924100 @default.
- W3199804663 hasConceptScore W3199804663C90924648 @default.
- W3199804663 hasLocation W31998046631 @default.
- W3199804663 hasLocation W31998046632 @default.
- W3199804663 hasOpenAccess W3199804663 @default.
- W3199804663 hasPrimaryLocation W31998046631 @default.
- W3199804663 hasRelatedWork W2074673535 @default.
- W3199804663 hasRelatedWork W2091225147 @default.
- W3199804663 hasRelatedWork W2143847100 @default.
- W3199804663 hasRelatedWork W2165563128 @default.
- W3199804663 hasRelatedWork W2166628562 @default.
- W3199804663 hasRelatedWork W2171303766 @default.
- W3199804663 hasRelatedWork W226179855 @default.
- W3199804663 hasRelatedWork W2508367408 @default.
- W3199804663 hasRelatedWork W2897315531 @default.
- W3199804663 hasRelatedWork W3199816176 @default.
- W3199804663 isParatext "false" @default.
- W3199804663 isRetracted "false" @default.
- W3199804663 magId "3199804663" @default.
- W3199804663 workType "article" @default.